Rheumatoid arthritis is not an endocrine disorder. It is classified as a systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. However, the hormonal system and RA are deeply intertwined, which is likely why this question comes up so often. Sex hormones, stress hormones, and thyroid function all influence who gets RA, how severe it becomes, and how it responds to treatment.
How RA Is Officially Classified
RA is a chronic inflammatory disorder caused by the immune system attacking the lining of the joints. The American College of Rheumatology and the European Alliance of Associations for Rheumatology maintain classification criteria that place RA firmly in the autoimmune category, not among endocrine conditions like diabetes or thyroid disease. The underlying problem is immune dysregulation: the body produces antibodies and inflammatory cells that target its own joint tissue, driven by a combination of genetic susceptibility and environmental triggers like smoking.
Endocrine disorders, by contrast, originate in hormone-producing glands and involve too much or too little of a specific hormone. RA doesn’t start in a gland, and no single hormone deficiency or excess causes it. That said, the relationship between hormones and RA is far more than incidental.
Why Hormones Play Such a Large Role
Estrogen, progesterone, and testosterone all bind to receptors inside immune cells, directly changing which genes those cells turn on or off. This means shifts in hormone levels can dial inflammation up or down in measurable ways. Estrogen, for example, generally suppresses the type of immune cells that drive RA inflammation. At high concentrations (like those seen in pregnancy), estrogen boosts production of anti-inflammatory signaling molecules while suppressing the pro-inflammatory ones that damage joints.
This is why reproductive life stages map so closely onto RA patterns in women. Postmenopausal women have 35% higher odds of developing RA compared to premenopausal women. Women who go through early menopause (before age 45) face nearly three times the odds of developing RA compared to those who reach menopause at a typical age. The drop in estrogen that comes with menopause removes a natural brake on the immune activity that fuels the disease.
Testosterone and RA Risk in Men
The hormonal connection isn’t limited to women. Men with low testosterone (below 300 ng/dL) have roughly 2.3 times the risk of developing RA compared to men with normal levels, even after accounting for age, weight, smoking, and other health conditions. As testosterone drops below that threshold, risk rises sharply. Men with RA also tend to have lower testosterone than healthy men of the same age.
Testosterone has anti-inflammatory effects similar to estrogen’s, so when levels fall, the immune system loses another layer of restraint. This helps explain why RA, while more common in women overall, also clusters among men with hormonal imbalances.
The Stress Hormone Connection
The body’s stress response system, known as the HPA axis (linking the brain to the adrenal glands), is frequently disrupted in people with RA. Under normal conditions, cortisol acts as a powerful anti-inflammatory hormone. In RA patients, chronic inflammation appears to wear down this system over time. Early on, cortisol levels may run high as the body tries to fight the inflammation. Eventually, the feedback loop breaks down, the adrenal glands become less responsive, and a state of relative cortisol deficiency can develop even while the body still shows signs of stress.
This creates a vicious cycle: the immune system is overactive, the stress response that should help control it becomes blunted, and inflammation worsens. Researchers have linked this kind of HPA axis dysfunction to the onset and flare-ups of several autoimmune diseases, RA included. It’s a genuine endocrine problem, but it’s a consequence of the autoimmune process rather than the root cause.
RA Treatment Can Create Endocrine Problems
Corticosteroids have been used to treat RA since 1948 and remain common for managing flares. These medications mimic cortisol, and when taken for more than a few weeks, they signal the brain to stop asking the adrenal glands to produce cortisol on their own. Over time, the adrenal glands can physically shrink from disuse.
If corticosteroids are stopped abruptly after prolonged use, the adrenal glands may not be able to pick up the slack. This is called secondary adrenal insufficiency, and symptoms include fatigue, weakness, nausea, weight loss, and muscle pain. Many of these overlap with RA symptoms themselves, making it easy to miss. The HPA axis typically recovers with a slow, gradual taper, but anyone who has taken corticosteroids for more than two consecutive weeks (or more than three cumulative weeks in the past six months) should have their adrenal function evaluated before stopping.
Thyroid Disease Overlaps With RA
People with RA are significantly more likely to develop autoimmune thyroid disease than the general population. In one Dutch study of 358 RA patients, clinical hypothyroidism was found in 6.8% compared to 2.7% in the general population. A Canadian survey found thyroid disease was three times more common among women with RA than among women with non-inflammatory joint conditions (30% vs. 11%). Thyroid antibodies, which signal autoimmune thyroid activity, appear at two to four times the rate seen in healthy controls.
This overlap isn’t because RA causes thyroid disease or vice versa. Both conditions share genetic risk factors, including a variant of the PTPN22 gene that has been linked to RA, type 1 diabetes, lupus, and Hashimoto’s thyroiditis. Having one autoimmune disease raises the odds of developing another, which is why screening for thyroid problems is worth discussing if you have RA.
RA Also Affects Metabolic Hormones
The inflammatory molecules that drive RA, particularly TNF-alpha, interfere with how the body responds to insulin. TNF-alpha blocks signaling through insulin receptors, which can lead to insulin resistance even in RA patients who are not overweight. In one study, RA patients with the lowest levels of inflammation still had higher insulin resistance than healthy controls, suggesting that the disease itself shifts metabolic function in ways that go beyond what standard inflammatory markers capture.
This metabolic disruption helps explain why people with RA face elevated cardiovascular risk. Insulin resistance promotes atherosclerosis, and when combined with the chronic inflammation of RA, the effect on blood vessels compounds over time.
Autoimmune, but Hormonally Entangled
RA sits in the autoimmune category because its core mechanism is immune-driven joint destruction. But hormones influence virtually every stage of the disease: who develops it, when it appears, how severe it becomes during different life phases, and what complications arise from treatment. The endocrine system doesn’t cause RA, but it shapes the disease in ways that are clinically significant and increasingly well understood.